Pioneering the Future of Cardiology: PMcardio Joins Forces with Cardiovascular Research Center Aalst in an AI-Driven R&D Partnership
July 17, 2023 08:04 ET
|
Powerful Medical
AALST, Belgium, July 17, 2023 (GLOBE NEWSWIRE) -- PMcardio, a market leader in AI-powered cardiovascular diagnostics, is thrilled to announce a research and development partnership with the...
Revolutionäre KI-gestützte Diagnostikplattform PMcardio jetzt in 15 weiteren europäischen Märkten für medizinische Fachkräfte zugänglich
July 11, 2023 03:04 ET
|
Powerful Medical
LONDON, July 11, 2023 (GLOBE NEWSWIRE) -- PMcardio, Markführer im Bereich der KI-gestützten Diagnostik von Herz-Kreislauf-Erkrankungen, gibt mit der Einführung seiner neuesten Version des Produkts...
PMcardio, la plateforme de diagnostic révolutionnaire alimentée par l'IA, est désormais accessible aux professionnels de la santé sur 15 nouveaux marchés européens
July 11, 2023 03:04 ET
|
Powerful Medical
LONDRES, 11 juill. 2023 (GLOBE NEWSWIRE) -- PMcardio, entreprise leader du diagnostic des maladies cardiovasculaires basé sur l'IA, annonce son expansion sur 15 marchés européens supplémentaires...
Revolutionary AI-Powered Diagnostics Platform PMcardio Now Accessible to Healthcare Professionals in 15 New European Markets
July 11, 2023 03:04 ET
|
Powerful Medical
LONDON, July 11, 2023 (GLOBE NEWSWIRE) -- PMcardio, a leading force in AI-powered diagnostics for cardiovascular diseases, announces expansion into 15 additional European markets with the launch of...
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
July 10, 2023 07:37 ET
|
ZyVersa Therapeutics
Mechanical stress on the heart, such as high blood pressure, initiates NLRP3-induced inflammation through heart-brain interactions, causing heart enlargement (hypertrophic heart disease) Mechanical...
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products
July 06, 2023 17:05 ET
|
Blue Water Biotech, Inc.
CINCINNATI, July 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and...
Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio
July 06, 2023 07:30 ET
|
Blue Water Biotech, Inc.
CINCINNATI, July 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and...
Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio
June 21, 2023 07:30 ET
|
Blue Water Biotech, Inc.
CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today...
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
June 14, 2023 07:30 ET
|
Blue Water Biotech, Inc.
CINCINNATI, Ohio, June 14, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), a biotechnology company spanning multiple sectors, today announced the signing of an Asset Purchase...
Venous Procedure Devices Market Poised for US$ 3.4 Billion Growth with a CAGR of 6% by 2030: As per TMR Study
June 02, 2023 06:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 02, 2023 (GLOBE NEWSWIRE) -- The market for venous procedure devices is expected to reach US$ 3.4 billion by 2030. From 2020 to 2030, the Venous Procedure...